Common Side Effects of Classic Chemotherapy
Classic chemotherapy drugs like platinum-based agents (e.g., cisplatin, carboplatin) or taxanes (e.g., paclitaxel) often cause:
- Severe nausea and vomiting, managed with antiemetics.
- High rates of hair loss (alopecia in 50-90% of patients).
- Significant myelosuppression, including neutropenia (low neutrophils, infection risk) and thrombocytopenia (low platelets, bleeding risk).
- Peripheral neuropathy (nerve damage leading to numbness or pain in hands/feet).
- Fatigue and mucositis (mouth sores).
These effects stem from non-selective cell killing, hitting rapidly dividing healthy cells in bone marrow, gut, and skin.1
Common Side Effects of Lurbinectedin (Zepzelca)
Lurbinectedin, approved for small cell lung cancer, targets the G2/M cell cycle phase via DNA damage repair inhibition. Its profile includes:
- Hematologic toxicity like neutropenia (58% all grades, 37% grade 3/4), anemia (46%), and thrombocytopenia (23%).
- Fatigue (42%), nausea (39%), decreased appetite (28%), and vomiting (22%).
- Transaminitis (elevated liver enzymes, ALT/AST increases in 35%).
- Lower rates of alopecia (only 9%) and neuropathy (3%).
GI effects are milder than classic chemo, with less severe vomiting.2
Key Differences in Side Effect Profiles
Lurbinectedin spares hair follicles and peripheral nerves more than classic chemo, resulting in:
- Reduced alopecia: 9% vs. 50-90%.
- Less neuropathy: 3% vs. 20-40% with taxanes or platinums.
- Milder nausea/vomiting: Primarily low-grade, without routine need for aggressive prophylaxis.
- Similar but manageable hematologic effects: Neutropenia is comparable in severity but often responds to G-CSF support; lurbinectedin has higher early-onset liver enzyme elevations.
Classic chemo hits broader toxicities from off-target effects, while lurbinectedin's mechanism yields a more targeted profile with prominent but reversible hematologic and hepatic issues. Prophylactic G-CSF is standard for lurbinectedin to mitigate neutropenia.2
Clinical Trial Data on Differences
In the phase 3 IMforte trial (lurbinectedin vs. topotecan, a classic chemo for SCLC), lurbinectedin showed:
- Lower discontinuation rates due to adverse events (18% vs. 36%).
- Fewer grade 3/4 events overall (72% vs. 82%).
- Superior tolerability, with patients staying on therapy longer.
Real-world data confirms less alopecia and neuropathy, improving quality of life.3
Patient Management and When Differences Matter
Patients switching from classic chemo to lurbinectedin often report better tolerance for outpatient treatment, though monitoring liver function and blood counts is critical. Differences shine in relapsed SCLC, where lurbinectedin's profile supports combination potential without compounding neuropathy.4
Sources: